Financial Performance - Total revenue for the fiscal year ending March 31, 2025, was approximately HKD 161.69 million, a decrease of about 10.71% compared to HKD 181.09 million in 2024[2] - Gross profit for the same period was approximately HKD 50.35 million, down approximately 8.03% from HKD 54.74 million in 2024[2] - Operating loss was approximately HKD 4.09 million, significantly reduced by about 89.63% from HKD 39.44 million in 2024[2] - Loss attributable to owners of the company was approximately HKD 6.62 million, a decrease of about 83.45% from HKD 39.98 million in 2024[2] - Basic and diluted loss per share was approximately HKD 0.0118, compared to HKD 0.0714 in 2024[4] - For the fiscal year ending March 31, 2025, the total revenue from external customers was HKD 161,693,000, a decrease of 10.7% from HKD 181,092,000 in the previous year[24] - The revenue from the blood dialysis treatment and consulting services segment was HKD 111,202,000, down 14.2% from HKD 129,556,000 in the prior year[24] - The total operating loss for the fiscal year ending March 31, 2025, was HKD 4,089,000, compared to a loss of HKD 39,438,000 in the previous year[15] - The company reported a pre-tax loss of HKD 5,492,000 for the fiscal year ending March 31, 2025[14] - The loss attributable to the company's owners for the year was approximately HKD 6,616,000, compared to a loss of HKD 39,977,000 in 2024[31] Assets and Liabilities - Total cash and cash equivalents as of March 31, 2025, were approximately HKD 24.08 million, an increase from HKD 18.23 million in 2024[2] - Non-current assets decreased from HKD 58.71 million in 2024 to HKD 50.21 million in 2025[5] - Current assets decreased slightly from HKD 58.39 million in 2024 to HKD 56.61 million in 2025[5] - The total assets as of March 31, 2025, amounted to HKD 106,822,000, a decrease from HKD 117,101,000 as of March 31, 2024[16] - The total liabilities as of March 31, 2025, were HKD 38,189,000, compared to HKD 41,906,000 in the previous year[16] - Trade receivables, net of expected credit loss provisions, were approximately HKD 25,074,000 as of March 31, 2025, down from HKD 37,907,000 in 2024[34] - Trade payables amounted to approximately HKD 6,896,000 as of March 31, 2025, compared to HKD 10,458,000 in 2024[36] - Total equity attributable to owners of the company decreased from HKD 73.49 million in 2024 to HKD 66.88 million in 2025[6] Dividends and Cash Flow - The company did not recommend a final dividend for the fiscal year ending March 31, 2025[2] - The company did not recommend the payment of a final dividend for the year ended March 31, 2025, consistent with the previous year[30] - The total cash and cash equivalents as of March 31, 2025, were approximately HKD 24,083,000, an increase from HKD 18,228,000 in 2024, due to improved trade receivables collection[51] Expenses and Cost Control - Sales and distribution expenses for the year ended March 31, 2025, were approximately HKD 32,041,000, a decrease of about 10.39% compared to HKD 35,758,000 in 2024 due to reduced marketing and logistics costs[44] - Administrative expenses for the year ended March 31, 2025, were approximately HKD 23,745,000, a decrease of about 20.29% from HKD 29,789,000 in 2024, primarily due to lower general office expenses[45] - Financial expenses for the year ended March 31, 2025, were approximately HKD 1,403,000, down about 18% from HKD 1,711,000 in 2024, attributed to reduced interest payments on borrowings[47] - The company implemented cost control measures, which contributed to a reduction in losses in the hemodialysis treatment segment compared to the previous year[41] Corporate Governance - The company has adopted the corporate governance code as its own, with the exception of the separation of roles between the Chairman and the CEO as per code provision C.2.1[67] - As of March 31, 2025, the company will not have a Chairman position, and the current board members will share the responsibilities of the Chairman[68] - Following the resignation of an independent non-executive director on April 30, 2024, the company will strive to fill the vacancy within three months to comply with listing rules[69] - The board currently consists of three independent non-executive directors, with at least one possessing appropriate professional qualifications or expertise in accounting or related financial management[70] - The audit committee held three meetings during the year ending March 31, 2025, to review and discuss the company's financial statements[73] - The remuneration committee has held three meetings during the year ending March 31, 2025, to review the remuneration of executive directors and senior management[78] - The nomination and corporate governance committee is currently chaired by an independent non-executive director and has been established to comply with relevant listing rules[79] - The audit committee is responsible for overseeing the independence and objectivity of external auditors and the effectiveness of audit procedures[74] - The company has adopted the standard code for securities transactions by directors since its listing date on October 11, 2013[71] - The company has received approval to extend the timeline for filling the vacancy of independent non-executive director until September 30, 2024[69] - The Nomination and Corporate Governance Committee held two meetings during the fiscal year ending March 31, 2025[82] Future Outlook - The company expects that the application of new Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements for the foreseeable future[11] - The company has not early adopted any new accounting standards that have been issued but are not yet effective[10] - The company will hold its Annual General Meeting on September 5, 2025, with a suspension of share transfer registration from September 2 to September 5, 2025[84] - The company expresses gratitude to the management team and employees for their efforts in achieving stable development[85] - The board consists of one executive director, one non-executive director, and three independent non-executive directors as of June 20, 2025[87]
万嘉集团(00401) - 2025 - 年度业绩